Current status of immunotherapy for non-small cell lung cancer

Current status of immunotherapy for non-small cell lung cancer

Nowadays, lung cancer is still the deadliest oncological disease in the world. Among them, non-small cell lung cancer (NSCLC) accounts for 80%∼85% of all lung cancers, and its 5-year survival rate is less than 15%, making the situation critical. In the past decades, despite some clinical advances in...

Full description

Bibliographic Details
Main Authors: Tao Yang, Yilin Xiong, Yufei Zeng, Yan Wang, Jing Zeng, Jie Liu, Shangfu Xu, Li-Sheng Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-10-01
Series:Frontiers in Pharmacology
Subjects:
non-small cell lung cancer
immunotherapy
antibody-drug conjugates
immune checkpoint inhibitor
bispecific antibodies
TCR-T and CAR-T therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.989461/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.989461/full

Similar Items